clinical trial · NCT06716307
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
Novo Nordisk A/S·phase1·completed·n = 18
ObesityCagriSema (cagrilintide B and semaglutide I)CagriSema A
brief summary
This study will compare the blood levels of cagrilintide and semaglutide when the same dose is given in two different versions of CagriSema. CagriSema is a medicine that combines two medicines called cagrilintide and semaglutide. It is still being tested in studies and is not yet available for doctors to prescribe. Participants will get an injection with each of the two versions of CagriSema at two different times at the clinic. Like all medicines, the study medicine may have side effects. The study will last for about 18 weeks.
started
Dec 2, 2024
primary completion
Mar 28, 2025
completion
May 22, 2025
last updated
Aug 27, 2025
official title
Comparing the Pharmacokinetics of Cagrilintide and Semaglutide Following Single Subcutaneous Doses of Different CagriSema Presentations, in a Crossover Manner in Adult Participants With Overweight or Obesity
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol